ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer. As a seasoned veteran with decades of commercial experience at McKesson, Novo Nordisk, Sanofi and Pfizer, Ms. Spencer-Pike will be responsible for accelerating the growth of the startup following its oversubscribed $56M Series A in October. Ms. Spencer-Pike follows a string of C-Suite appointments including Geoff Johnson, M.D., Ph.D. as Chief Scientific Officer, Kevin Haehl as Chief Development Officer and Mark Przekop as Chief Operating Officer.
“Kathy’s sterling track record of enhancing organizational value, paired with her expertise in creating, developing, and leading high-achieving teams in new business, client success, and business expansion is the perfect addition to round out our C-Suite,” said Charles S. Conroy, CEO of Nucleus RadioPharma. “On the heels of our successful funding round to increase the radiopharmaceutical accessibility, we are eager to lean on Kathy’s experience and insight to accelerate further growth and advance our commitment to delivering life-saving treatments to patients with cancer.”
Before Nucleus, Ms. Spencer-Pike was Chief Sales Officer at McKesson where she spurred significant company growth, built a high-performance commercial team and merged three legacy organizations into a single commercial organization achieving unprecedented double-digit growth year over year. Ms. Spencer-Pike previously was VP, Commercial Leader for Novo Nordisk, successfully leading the planning, development and execution of market and sales strategies, exceeding revenue goals. In addition to her commercial experience, Ms. Spencer-Pike is a dedicated advocate for DE&I, leading the largest US-based Women’s Employee Resource Group (ERG) at Pfizer and Novo Nordisk, both of which were the largest ERGs within the companies. This experience speaks to her commitment to growth and development and fostering inclusive cultures.
Please visit https://nucleusrad.com/#about for more information and to learn more about Nucleus RadioPharma’s partnering opportunities.
About Nucleus RadioPharma
Nucleus RadioPharma is a Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies. Nucleus RadioPharma's mission is to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new treatment tools.